Centro de Imagem Diagnósticos S.A (AALR3) Fair Value & Analysis

Healthcare · BR · Market cap R$513M (≈ $99.4M) · ISIN BRAALRACNOR6

Below-average quality, trading 54% below our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case (R$3.47). The market is more pessimistic than our downside scenario.
• The model range is unusually wide (R$3.47 to R$9.45). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range R$2.56 – R$24.30 · fair‑value band R$3.47 – R$9.45 · the R$2.96 price screens below the R$6.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Centro de Imagem Diagnósticos S.A (AALR3) currently trades at R$2.96, while our model-based Fair Value estimate is R$6.46, implying the stock looks roughly 118.2% undervalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Centro de Imagem Diagnósticos S.A generated revenue of R$1.2B at a net margin of -6.5%. Revenue grew 3.3% year over year. It earns a return on equity of -6.2%. Net debt stands at R$836M. Fundamentals as of Aug 13, 2026

Our scenario range runs from R$3.47 (bear case) to R$9.45 (bull case); at R$2.96, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 57% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at 118%, AALR3 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (R$9.90) versus Dividend Discount (R$1.26). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

Alliança Saúde e Participações S.A. provides diagnostic imaging and medicine services in Brazil. The company offers diagnostic imaging, clinical analysis, nuclear medicine, genetic testing, and vaccination services, as well as corporate, remote, and in-person solutions for hospitals and diagnostic centers in the private and public sectors.

Full company description

Alliança Saúde e Participações S.A. provides diagnostic imaging and medicine services in Brazil. The company offers diagnostic imaging, clinical analysis, nuclear medicine, genetic testing, and vaccination services, as well as corporate, remote, and in-person solutions for hospitals and diagnostic centers in the private and public sectors. It provides clinical analysis services, such as blood count, cholesterol, triglycerides, urinalysis 1, stool test, detection of sexually transmitted diseases, and anatomical pathology; and diagnostic imaging services, such as magnetic resonance, computed tomography, ultrasound, x-rays, bone densitometry, mammography, scintigraphy, and PET-CT (positron emission tomography " computed tomography). It also offers graphic methods examinations, including electrocardiogram, cardiotocography, Holter, ergometric tests, and cardiopulmonary tests. Alliança Saúde e Participações S.A. was formerly known as Centro de Imagem Diagnósticos S.A. and changed its name to Alliança Saúde e Participações S.A. in April 2023. Alliança Saúde e Participações S.A. was founded in 1992 and is based in São Paulo, Brazil.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Centro de Imagem Diagnósticos S.A reported revenue of R$1.2B in FY2024 versus R$929M in FY2020, a compound +7.0%/yr. Reported net income was −R$129M in FY2024.

Watch AALR3: get an alert when its fair value changes →

Peer Group

Diagnostics & Research · 140 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Diagnostics & Research median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.